Neue Indolderivate als FLT3-Inhibitoren und chimäre FLT3- und HDAC-Inhibitoren: Synthese und biologische Testung
- Alternative title
-
New indole derivatives as FLT3 inhibitors and chimeric FLT3- and HDAC inhibitors: synthesis and biological evaluation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Deutsch
- Notes
-
Regensburg, Universität Regensburg, Dissertation, 2020
- Keyword
-
Inhibitor
Indolderivate
Chemische Synthese
Histon-Deacetylase
- Event
-
Veröffentlichung
- (where)
-
Regensburg
- (who)
-
Universitätsbibliothek Regensburg
- (when)
-
2022
- Creator
-
Pilsl, Bernadette
- Contributor
-
Mahboobi, Siavosh
- URN
-
urn:nbn:de:bvb:355-epub-443938
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pilsl, Bernadette
- Mahboobi, Siavosh
- Universitätsbibliothek Regensburg
Time of origin
- 2022
Other Objects (12)
FLT3 inhibitors in acute myeloid leukemia
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Evaluierung des biologischen Effekts von FLT3 und SRC-Inhibitoren auf FLT3-Mutationen im murinen und humanen Zellsystem
Evaluierung des biologischen Effekts von FLT3 und SRC Inhibitoren auf FLT3-Mutationen im murinen und humanen Zellsystem
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
FLT3 inhibitors in acute myeloid leukemia
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Evaluierung des biologischen Effekts von FLT3 und SRC-Inhibitoren auf FLT3-Mutationen im murinen und humanen Zellsystem
Evaluierung des biologischen Effekts von FLT3 und SRC Inhibitoren auf FLT3-Mutationen im murinen und humanen Zellsystem
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
FLT3 inhibitors in acute myeloid leukemia
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Evaluierung des biologischen Effekts von FLT3 und SRC-Inhibitoren auf FLT3-Mutationen im murinen und humanen Zellsystem
Evaluierung des biologischen Effekts von FLT3 und SRC Inhibitoren auf FLT3-Mutationen im murinen und humanen Zellsystem
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors